Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as vital components of precision medicine, have demonstrated tremendous potential in the field of gene therapy.

Among the many immune checkpoint inhibitors, Durvalumab (brand name Imfinzi) stands out as particularly noteworthy.

siRNA (small interfering RNA) drugs and ASO (antisense oligonucleotide) drugs, as the two pillars of the small nucleic acid therapeutics field.

In modern gene therapy, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are key nucleic acid drugs that offer new treatment options for genetic and complex diseases.

Tisotumab Vedotin-tftv is an antibody-drug conjugate (ADC) developed by Genmab and Seagen, a protein that is overexpressed in various solid tumors.

Tofersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the superoxide dismutase 1 (SOD1) mRNA.

Ustekinumab, also known by its brand name Stelara, is a groundbreaking drug targeting interleukin-12 (IL-12) and interleukin-23 (IL-23).

Plozasiran, a novel therapeutic agent, is a small interfering RNA (siRNA) developed by Silence Therapeutics.

Sacituzumab govitecan-hziy, also known as Trodelvy, is an antibody-drug conjugate (ADC) developed by Immunomedics, now part of Gilead Sciences.

Pegaptanib, developed by EyeTech Pharmaceuticals and later acquired by OSI Pharmaceuticals, is a pegylated aptamer that targets VEGF.

Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R).

Polatuzumab Vedotin-Piiq, also known as Polivy, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.